<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468182</url>
  </required_header>
  <id_info>
    <org_study_id>0220060228</org_study_id>
    <nct_id>NCT00468182</nct_id>
  </id_info>
  <brief_title>Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis</brief_title>
  <official_title>Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether interferon-beta impairs the ability of
      plasmacytoid dendritic cells to promote pathogenic immune responses in patients with multiple
      sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative gene expression in plasmacytoid dendritic cells (pDCs)</measure>
    <time_frame>Change in gene expression in 12 weeks</time_frame>
    <description>Gene expression is tested in pDCs separetd from peripheral blood of human subjects at baseline and at 12 weeks</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>MS patients or patients with CIS (Clinically isolated syndrome) who decided to be treated with IFN-beta for 3 months (with the option to continue Rx)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>MS patients or patients with CIS(Clinically isolated syndrome)who decided to postpone the treatment with IFN-beta</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-beta 1b (Betaseron)</intervention_name>
    <description>Treatment of patients with FDA-approved Rx</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Multiple Sclerosis Clinic patient
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 18 to 60 year old, inclusive.

          -  Diagnosis of a relapsing form of multiple sclerosis as determined by revised McDonald
             Criteria or at least one clinical demyelinating episode with abnormal brain MRI study
             based on CHAMPS criteria

          -  Expanded disability status scale (EDSS) score less than 6 at entry.

          -  Understand and sign written informed consent prior to any testing under this protocol,
             including screening tests and evaluations that are not considered part of the
             subject's routine care.

        Exclusion Criteria:

          -  Treatment with corticosteroids within one month prior to the study. Treatment with
             immunomodulatory drugs within last 3 months prior to the study.

          -  No history of treatment with Interferon-beta(IFN-beta) based drugs to exclude the
             possibility of IFN-beta neutralizing antibodies

          -  Any patient who is pregnant, intend to become pregnant, or breastfeeding at any time
             of the study.

          -  History of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal
             disease; immune deficiency; or other medical conditions that would preclude IFN-beta
             therapy.

          -  Primary Progressive Multiple Sclerosis patients or patients with Secondary Progressive
             Multiple Sclerosis with lack of recent clinical relapses for more than 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantin Balashov, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Robert Wood Johnson Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rutgers-RWJMS</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aung LL, Brooks A, Greenberg SA, Rosenberg ML, Dhib-Jalbut S, Balashov KE. Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells. J Neuroimmunol. 2012 Sep 15;250(1-2):99-105. doi: 10.1016/j.jneuroim.2012.05.013. Epub 2012 Jun 9.</citation>
    <PMID>22688425</PMID>
  </reference>
  <results_reference>
    <citation>Balashov KE, Aung LL, Vaknin-Dembinsky A, Dhib-Jalbut S, Weiner HL. Interferon-Î² inhibits toll-like receptor 9 processing in multiple sclerosis. Ann Neurol. 2010 Dec;68(6):899-906. doi: 10.1002/ana.22136.</citation>
    <PMID>21061396</PMID>
  </results_reference>
  <results_reference>
    <citation>Aung LL, Fitzgerald-Bocarsly P, Dhib-Jalbut S, Balashov K. Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta. J Neuroimmunol. 2010 Sep 14;226(1-2):158-64. doi: 10.1016/j.jneuroim.2010.06.008.</citation>
    <PMID>20621365</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2007</study_first_submitted>
  <study_first_submitted_qc>April 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2007</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Konstantin Balashov</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Interferon beta</keyword>
  <keyword>plasmacytoid dendritic cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

